Prior findings by Dr. Liau were that the additional in vitro tumor debris caused by better resections supplies a richer source of antigens (which is in addition to the dead tumor lysate provided by the removed tumor).
As you point out, another feature that "softeners" like chemoradiation provide are reduced resilience by the tumor to immunosuppress the dendritic cells. This can also be done through processes like local and/or general hyperthermia, radio-frequency ablation, etc. Clinically induced hyperthermia has the added benefit of stimulating the overall immune response.
Moving on to DCVax-Direct, and future DCVAX-L Advanced with Direct manufacturing, the resilience to the immunosuppressive environment is much stronger, the signaling capabilities are increased ten-fold, the immediate tumor cell killing ability to provide tumor debris for uptake is enhanced, the migration capability to the lymphs is enhanced, expression is enhanced and consequently the T and B cell targeted infiltration response is enhanced.
Thus for Direct (and probably future advanced DCVAX-L), the risks associated with combined chemoradiation may outweigh the benefits compared to other therapeutic enhancements like:
1. Direct + radiation (no chemo)
2. Direct plus local hyperthermia
3. Direct plus general hypethermia
4. Direct plus radofrequency ablation
5. Etc.
Market Data 
Markets 
AI
